<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37892724</PMID><DateRevised><Year>2023</Year><Month>10</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>20</Issue><PubDate><Year>2023</Year><Month>Oct</Month><Day>18</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle>Patterns of Opioid and Non-Opioid Analgesic Consumption in Patients with Post-COVID-19 Conditions.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">6586</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm12206586</ELocationID><Abstract><AbstractText>Pain is a major health issue for healthcare systems, and access to pain treatment is a fundamental human right. Pain is a common symptom experienced in the post-COVID phase by a significant percentage of patients. This study describes the prevalence and associated factors associated with the use of opioid and non-opioid analgesics in subjects with post-COVID-19 condition. Sociodemographic data, post-COVID symptoms, health profile, and opioid and non-opioid analgesic consumption were collected in 390 subjects with post-COVID-19 condition. We analyzed the independent effect of all variables on opioid/non-opioid analgesic consumption by using logistic multivariate regressions. The prevalence of opioid and non-opioid analgesic consumption was 24.1% and 82.3%, respectively. Tramadol (17.18%) and codeine (7.95%) were the most commonly used opioid analgesics, and Paracetamol (70%) and ibuprofen (45.4%) were the most commonly used non-opioid analgesics. Females were more likely to consume non-opioid analgesics (aOR2.20, 95%CI 1.15, 4.22) than males. Marital status of married/partner vs. single (aOR2.96; 95% CI 1.43, 6.12), monthly income &lt; EUR 1000 VS. &gt; EUR 2000 (aOR3.81; 95% CI 1.37, 10.61), number of post-COVID symptoms &lt; 5 (aOR2.64, 95%CI 1.18, 5.87), and anxiolytics consumption (aOR 1.85, 95%CI 1.05, 3.25) were associated with a greater likelihood of opioid analgesic consumption. Age &gt; 55 years (aOR3.30, 95%CI 1.34, 8.09) and anxiolytics consumption (aOR2.61, 95%CI 1.36, 4.98) were associated with a greater likelihood of non-opioid analgesic consumption. Opioid analgesic consumption was highly associated (aOR 3.41, 95%CI 1.27, 6.11) with non-opioid analgesic consumption. The prevalence of opioid analgesic and non-opioid analgesic consumption in individuals with post-COVID-19 condition was 24.1% and 82.3%. Females with post-COVID-19 condition showed higher non-opioid analgesic consumption than men. Predictors of opioid consumption were marital status, lower monthly income, number of post-COVID symptoms, and anxiolytic consumption. Older age and anxiolytic consumption were predictors of non-opioid consumption.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Carrasco-Garrido</LastName><ForeName>Pilar</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-3000-6748</Identifier><AffiliationInfo><Affiliation>Department of Medical Specialties and Public Health, Health Sciences Faculty, Universidad Rey Juan Carlos, Avenida Atenas s/n, Alcorcon, 28922 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Preventive Medicine and Public Health Teaching and Research Unit, Health Sciences Faculty, Rey Juan Carlos University, Avda. Atenas s/n. Alcorc&#xf3;n, 28922 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palacios-Ce&#xf1;a</LastName><ForeName>Domingo</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-0669-6339</Identifier><AffiliationInfo><Affiliation>Department of Physical Therapy, Occupational Therapy, Rehabilitation and Physical Medicine, Health Sciences Faculty, Universidad Rey Juan Carlos, Avenida Atenas s/n, Alcorcon, 28922 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hern&#xe1;ndez-Barrera</LastName><ForeName>Valent&#xed;n</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Medical Specialties and Public Health, Health Sciences Faculty, Universidad Rey Juan Carlos, Avenida Atenas s/n, Alcorcon, 28922 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jim&#xe9;nez-Trujillo</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-9394-6799</Identifier><AffiliationInfo><Affiliation>Department of Medical Specialties and Public Health, Health Sciences Faculty, Universidad Rey Juan Carlos, Avenida Atenas s/n, Alcorcon, 28922 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallardo-Pino</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medical Specialties and Public Health, Health Sciences Faculty, Universidad Rey Juan Carlos, Avenida Atenas s/n, Alcorcon, 28922 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-de-Las-Pe&#xf1;as</LastName><ForeName>Cesar</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-3772-9690</Identifier><AffiliationInfo><Affiliation>Department of Physical Therapy, Occupational Therapy, Rehabilitation and Physical Medicine, Health Sciences Faculty, Universidad Rey Juan Carlos, Avenida Atenas s/n, Alcorcon, 28922 Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Grant/Award Number: 2014-2020</GrantID><Agency>Recursos REACT-UE del Programa Operativo de Madrid, Grant/Award Number: 2014-2020; Comunidad de Madrid y la Uni&#xf3;n Europea.</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">long-COVID</Keyword><Keyword MajorTopicYN="N">non-opioids</Keyword><Keyword MajorTopicYN="N">opioids</Keyword><Keyword MajorTopicYN="N">predictors</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>9</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>28</Day><Hour>11</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>28</Day><Hour>11</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>28</Day><Hour>1</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>10</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37892724</ArticleId><ArticleId IdType="pmc">PMC10607000</ArticleId><ArticleId IdType="doi">10.3390/jcm12206586</ArticleId><ArticleId IdType="pii">jcm12206586</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sun P., Qie S., Liu Z., Ren J., Li K., Xi J. Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: A single arm meta-analysis. J. Med. Virol. 2020;92:612&#x2013;617. doi: 10.1002/jmv.25735.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25735</ArticleId><ArticleId IdType="pmc">PMC7228255</ArticleId><ArticleId IdType="pubmed">32108351</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciaffi J., Meliconi R., Ruscitti P., Berardicurti O., Giacomelli R., Ursini F. Rheumatic manifestations of COVID-19: A systematic review and meta-analysis. BMC Rheumatol. 2020;4:65. doi: 10.1186/s41927-020-00165-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41927-020-00165-0</ArticleId><ArticleId IdType="pmc">PMC7591274</ArticleId><ArticleId IdType="pubmed">33123675</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdullahi A., Candan S.A., Abba M.A., Bello A.H., Alshehri M.A., Afamefuna Victor E., Umar N.A. Kundakci B Neurological and musculoskeletal features of COVID-19: A systematic review and meta-analysis. Front. Neurol. 2020;11:687. doi: 10.3389/fneur.2020.00687.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.00687</ArticleId><ArticleId IdType="pmc">PMC7333777</ArticleId><ArticleId IdType="pubmed">32676052</ArticleId></ArticleIdList></Reference><Reference><Citation>Caronna E., Pozo-Rosich P. Headache as a symptom of COVID-19: Narrative review of 1-year research. Curr. Pain. Headache Rep. 2021;25:73. doi: 10.1007/s11916-021-00987-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11916-021-00987-8</ArticleId><ArticleId IdType="pmc">PMC8583579</ArticleId><ArticleId IdType="pubmed">34766205</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocha-Filho P.A.S. Headache associated with COVID-19: Epidemiology, characteristics, pathophysiology and management. Headache. 2022;62:650&#x2013;656. doi: 10.1111/head.14319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/head.14319</ArticleId><ArticleId IdType="pmc">PMC9348060</ArticleId><ArticleId IdType="pubmed">35545780</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-Las-Pe&#xf1;as C., Palacios-Ce&#xf1;a D., G&#xf3;mez-Mayordomo V., Florencio L.L., Cuadrado M.L., Plaza-Manzano G., Navarro-Santana M. Prevalence of post-COVID-19 symptoms in hospitalized and non-hospitalized COVID-19 survivors: A systematic review and meta-analysis. Eur. J. Int. Med. 2021;92:55&#x2013;70. doi: 10.1016/j.ejim.2021.06.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejim.2021.06.009</ArticleId><ArticleId IdType="pmc">PMC8206636</ArticleId><ArticleId IdType="pubmed">34167876</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C., Haupert S.R., Zimmermann L., Shi X., Fritsche L.G., Mukherjee B. Global prevalence of post COVID-19 condition or long COVID: A meta-analysis and systematic review. J. Infect. Dis. 2022:jiac136. doi: 10.1093/infdis/jiac136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac136</ArticleId><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as C. Long COVID: Current definition. Infection. 2022;50:285&#x2013;286. doi: 10.1007/s15010-021-01696-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-021-01696-5</ArticleId><ArticleId IdType="pmc">PMC8438555</ArticleId><ArticleId IdType="pubmed">34519974</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano J.B., Murthy S., Marshall J.C., Relan P., Diaz J.V. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect. Dis. 2022;22:102&#x2013;107. doi: 10.1016/S1473-3099(21)00703-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as C., Navarro-Santana M., Plaza-Manzano G., Palacios-Ce&#xf1;a D., Arendt-Nielsen L. Time course prevalence of post-COVID pain symptoms of musculoskeletal origin in patients who had survived severe acute respiratory syndrome coronavirus 2 infection: A systematic review and meta-analysis. Pain. 2022;163:1220&#x2013;1231. doi: 10.1097/j.pain.0000000000002496.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/j.pain.0000000000002496</ArticleId><ArticleId IdType="pubmed">34561390</ArticleId></ArticleIdList></Reference><Reference><Citation>Bileviciute-Ljungar I., Norrefalk J.R., Borg K. Pain burden in post-COVID-19 syndrome following mild COVID-19 infection. J. Clin. Med. 2022;11:771. doi: 10.3390/jcm11030771.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11030771</ArticleId><ArticleId IdType="pmc">PMC8836662</ArticleId><ArticleId IdType="pubmed">35160223</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as C., de-la-Llave-Rinc&#xf3;n A.I., Ortega-Santiago R., Ambite-Quesada S., G&#xf3;mez-Mayordomo V., Cuadrado M.L., Arias-Naval&#xf3;n J.A., Hern&#xe1;ndez-Barrera V., Mart&#xed;n-Guerrero J.D., Pellicer-Valero O.J., et al. Prevalence and risk factors of musculoskeletal pain symptoms as long-term post-COVID sequelae in hospitalized COVID-19 survivors: A multicenter study. Pain. 2022;163:e989&#x2013;e996. doi: 10.1097/j.pain.0000000000002564.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/j.pain.0000000000002564</ArticleId><ArticleId IdType="pubmed">34913880</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as C., Navarro-Santana M., G&#xf3;mez-Mayordomo V., Cuadrado M.L., Garc&#xed;a-Azor&#xed;n D., Arendt-Nielsen L., Plaza-Manzano G. Headache as an acute and post-COVID-19 symptom in COVID-19 survivors: A meta-analysis of the current literature. Eur. J. Neurol. 2021;28:3820&#x2013;3825. doi: 10.1111/ene.15040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.15040</ArticleId><ArticleId IdType="pmc">PMC8444899</ArticleId><ArticleId IdType="pubmed">34327787</ArticleId></ArticleIdList></Reference><Reference><Citation>Premraj L., Kannapadi N.V., Briggs J., Seal S.M., Battaglini D., Fanning J., Suen J., Robba C., Fraser J., Cho S.M. Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: A meta-analysis. J. Neurol. Sci. 2022;434:120162. doi: 10.1016/j.jns.2022.120162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2022.120162</ArticleId><ArticleId IdType="pmc">PMC8798975</ArticleId><ArticleId IdType="pubmed">35121209</ArticleId></ArticleIdList></Reference><Reference><Citation>Aiyegbusi O.L., Hughes S.E., Turner G., Rivera S.C., McMullan C., Chandan J.S., Haroon S., Price G., Davies E.H., Nirantharakumar K., et al. Symptoms, complications and management of long COVID: A review. J. R. Soc. Med. 2021;114:428&#x2013;442. doi: 10.1177/01410768211032850.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/01410768211032850</ArticleId><ArticleId IdType="pmc">PMC8450986</ArticleId><ArticleId IdType="pubmed">34265229</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippi G., Mattiuzzi C. Internet searches for over-the-counter analgesics during the COVID-19 pandemic outbreak in Italy. Pain Med. 2021;22:1885&#x2013;1886. doi: 10.1093/pm/pnaa485.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/pm/pnaa485</ArticleId><ArticleId IdType="pmc">PMC7989177</ArticleId><ArticleId IdType="pubmed">33706368</ArticleId></ArticleIdList></Reference><Reference><Citation>Do T.P., Do H.Q. Internet search interest for over-the-counter analgesics during the COVID-19 Pandemic. Pain Med. 2021;22:2407&#x2013;2418. doi: 10.1093/pm/pnaa434.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/pm/pnaa434</ArticleId><ArticleId IdType="pmc">PMC7717436</ArticleId><ArticleId IdType="pubmed">33211095</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyce A.A., Conger A., McCormick Z.L., Kendall R.W., Wagner G., Teramoto M., Cushman D.M. Changes in interventional pain physician decision-making, practice patterns, and mental health during the early phase of the SARS-CoV-2 Global Pandemic. Pain Med. 2020;21:3585&#x2013;3595. doi: 10.1093/pm/pnaa294.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/pm/pnaa294</ArticleId><ArticleId IdType="pmc">PMC7499755</ArticleId><ArticleId IdType="pubmed">32866247</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee B., Yang K.C., Kaminski P., Peng S., Odabas M., Gupta S., Green H.D., Jr., Ahn Y.Y., Perry B.L. Substitution of nonpharmacologic therapy with opioid prescribing for pain during the COVID-19 pandemic. JAMA Netw. Open. 2021;4:e2138453. doi: 10.1001/jamanetworkopen.2021.38453.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.38453</ArticleId><ArticleId IdType="pmc">PMC8665369</ArticleId><ArticleId IdType="pubmed">34889946</ArticleId></ArticleIdList></Reference><Reference><Citation>Agencia Espa&#xf1;ola de Medicamentos y Productos Sanitarios  Utilizaci&#xf3;n de Medicamentos Opioides en Espa&#xf1;a. 2021.  [(accessed on 18 September 2022)].  Available online:  https://www.aemps.gob.es/medicamentos-de-uso-humano/observatorio-de-uso-de-medicamentos/utilizacion-de-medicamentos-opioides-en-espana/</Citation></Reference><Reference><Citation>Agencia Espa&#xf1;ola de Medicamentos y Productos Sanitarios  Utilizaci&#xf3;n de Medicamentos Analg&#xe9;sicos No Opioides en Espa&#xf1;a. 2021.  [(accessed on 18 September 2022)].  Available online:  https://www.aemps.gob.es/medicamentos-de-uso-humano/observatorio-de-uso-de-medicamentos/utilizacion-de-medicamentos-analgesicos-no-opioides-en-espana/</Citation></Reference><Reference><Citation>Mirahmadizadeh A., Heiran A., Dadvar A., Moradian M.J., Sharifi M.H., Sahebi R. The association of opium abuse with mortality amongst hospitalized COVID-19 patients in Iranian Population. J. Prev. 2022;43:485&#x2013;497. doi: 10.1007/s10935-022-00687-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10935-022-00687-y</ArticleId><ArticleId IdType="pmc">PMC9161650</ArticleId><ArticleId IdType="pubmed">35653048</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosmer D.W., Lemeshow S., Sturdivant R.X. Applied Logistic Regression. 3rd ed. John Wiley &amp; Sons, Inc; Hoboken, NJ, USA: 2013.</Citation></Reference><Reference><Citation>Currie J.M., Schnell M.K., Schwandt H., Zhang J. Prescribing of Opioid Analgesics and Buprenorphine for Opioid Use Disorder During the COVID-19 Pandemic. JAMA Netw. Open. 2021;4:e216147. doi: 10.1001/jamanetworkopen.2021.6147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.6147</ArticleId><ArticleId IdType="pmc">PMC8050741</ArticleId><ArticleId IdType="pubmed">33856474</ArticleId></ArticleIdList></Reference><Reference><Citation>Mun C.J., Campbell C.M., McGill L.S., Wegener S.T., Aaron R.V. Trajectories and Individual Differences in Pain, Emotional Distress, and Prescription Opioid Misuse During the COVID-19 Pandemic: A One-Year Longitudinal Study. J. Pain. 2022;23:1234&#x2013;1244. doi: 10.1016/j.jpain.2022.02.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpain.2022.02.005</ArticleId><ArticleId IdType="pmc">PMC8898783</ArticleId><ArticleId IdType="pubmed">35272053</ArticleId></ArticleIdList></Reference><Reference><Citation>Robb C.T., Goepp M., Rossi A.G., Yao C. Non-steroidal anti-inflammatory drugs, prostaglandins, and COVID-19. Br. J. Pharmacol. 2020;177:4899&#x2013;4920. doi: 10.1111/bph.15206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.15206</ArticleId><ArticleId IdType="pmc">PMC7405053</ArticleId><ArticleId IdType="pubmed">32700336</ArticleId></ArticleIdList></Reference><Reference><Citation>Little P. Non-steroidal anti-inflammatory drugs and COVID-19. BMJ. 2020;368:m1185. doi: 10.1136/bmj.m1185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m1185</ArticleId><ArticleId IdType="pubmed">32220865</ArticleId></ArticleIdList></Reference><Reference><Citation>Downs C.G., Varisco T.J., Bapat S.S., Shen C., Thornton J.D. Impact of COVID-19 related policy changes on filling of opioid and benzodiazepine medications. Res. Soc. Adm. Pharm. 2021;17:2005&#x2013;2008. doi: 10.1016/j.sapharm.2020.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sapharm.2020.06.003</ArticleId><ArticleId IdType="pmc">PMC7738763</ArticleId><ArticleId IdType="pubmed">33317769</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosetti C., Santucci C., Radrezza S., Erthal J., Berterame S., Corli O. Trends in the consumption of opioids for the treatment of severe pain in Europe, 1990-2016. Eur. J. Pain. 2019;23:697&#x2013;707. doi: 10.1002/ejp.1337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejp.1337</ArticleId><ArticleId IdType="pubmed">30407692</ArticleId></ArticleIdList></Reference><Reference><Citation>US Department of Health and Human Services  HHS.GOV/OPIOIDS. What Is the U.S. Opioid Epidemic?  [(accessed on 14 October 2022)]; Available online:  https://www.hhs.gov/opioids/about-the-epidemic/index.html.</Citation></Reference><Reference><Citation>Canadian Centre of Substance Use and Addiction  Prescription Opioids 2020. (Canadian Drug Summary)  [(accessed on 14 October 2022)].  Available online:  https://www.ccsa.ca/prescription-opioids-canadian-drug-summary.</Citation></Reference><Reference><Citation>Kalkman G.A., Kramers C., van Dongen R.T., van den Brink W., Schellekens A. Trends in use and misuse of opioids in the Netherlands: A retrospective, multi- source database study. Lancet Public Health. 2019;4:e498&#x2013;e505. doi: 10.1016/S2468-2667(19)30128-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-2667(19)30128-8</ArticleId><ArticleId IdType="pubmed">31444001</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller A.E., Clausen T., Sj&#xf8;gren P., Odsbu I., Skurtveit S. Prescribed opioid analgesic use developments in three Nordic countries, 2006&#x2013;2017. Scand J. Pain. 2019;19:345&#x2013;353. doi: 10.1515/sjpain-2018-0307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/sjpain-2018-0307</ArticleId><ArticleId IdType="pubmed">30677000</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwanicki J.L., Schwarz J., May K.P., Black J.C., Dart R.C. Tramadol non-medical use in Four European countries: A comparative analysis. Drug Alcohol. Depend. 2020;217:108367. doi: 10.1016/j.drugalcdep.2020.108367.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drugalcdep.2020.108367</ArticleId><ArticleId IdType="pubmed">33153831</ArticleId></ArticleIdList></Reference><Reference><Citation>Reines S.A., Goldmann B., Harnett M., Lu L. Misuse of Tramadol in the United States: An Analysis of the National Survey of Drug Use and Health 2002&#x2013;2017. Subst. Abuse. 2020;14:1178221820930006. doi: 10.1177/1178221820930006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1178221820930006</ArticleId><ArticleId IdType="pmc">PMC7271275</ArticleId><ArticleId IdType="pubmed">32547049</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigal L.M., Bibeau K., Dunbar S. Tramadol Prescription over a 4-Year Period in the USA. Curr. Pain Headache Rep. 2019;23:76. doi: 10.1007/s11916-019-0777-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11916-019-0777-x</ArticleId><ArticleId IdType="pubmed">31388761</ArticleId></ArticleIdList></Reference><Reference><Citation>Wells J.S., Bergin M., Van Hout M.C., McGuinness P., De Pleissisc J., Rich E., Dada S., Wells R., Gooney M.A. Purchasing Over The Counter (OTC) Medicinal Products Containing Codeine&#x2014;Easy Access, Advertising, Misuse and Perceptions of Medicinal Risk. J. Pharm. Pharm. Sci. 2018;21:30049. doi: 10.18433/jpps30049.</Citation><ArticleIdList><ArticleId IdType="doi">10.18433/jpps30049</ArticleId><ArticleId IdType="pubmed">30011259</ArticleId></ArticleIdList></Reference><Reference><Citation>Membrilla J.A., de Lorenzo &#xcd;., Sastre M., D&#xed;az de Ter&#xe1;n J. Headache as a cardinal symptom of coronavirus disease 2019 a cross-sectional study. Headache. 2020;60:2176&#x2013;2191. doi: 10.1111/head.13967.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/head.13967</ArticleId><ArticleId IdType="pmc">PMC7646273</ArticleId><ArticleId IdType="pubmed">32989732</ArticleId></ArticleIdList></Reference><Reference><Citation>Nino-Orrego M.J., Baracaldo-Santamar&#xed;a D., Patricia Ortiz C., Zuluaga H.P., Cruz-Becerra S.A., Soler F., P&#xe9;rez-Acosta A.M., Delgado D.R., Calderon-Ospina C.A. Prescription for COVID-19 by non-medical professionals during the pandemic in Colombia: A cross-sectional study. Ther. Adv. Drug Saf. 2022;13:20420986221101964. doi: 10.1177/20420986221101964.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/20420986221101964</ArticleId><ArticleId IdType="pmc">PMC9136451</ArticleId><ArticleId IdType="pubmed">35646306</ArticleId></ArticleIdList></Reference><Reference><Citation>Dale O., Borchgrevink P.C., Fredheim O.M., Mahic M., Romundstad P., Skurtveit S. Prevalence of use of non-prescription analgesics in the Norwegian HUNT3 population: Impact of gender, age, exercise and prescription of opioids. BMC Public Health. 2015;15:461. doi: 10.1186/s12889-015-1774-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-015-1774-6</ArticleId><ArticleId IdType="pmc">PMC4428499</ArticleId><ArticleId IdType="pubmed">25934132</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;nchez-S&#xe1;nchez E., Fern&#xe1;ndez-Cerezo F.L., D&#xed;az-Jimenez J., Rosety-Rodriguez M., D&#xed;az A.J., Ordonez F.J., Rosety M.&#xc1;., Rosety I. Consumption of over-the-Counter Drugs: Prevalence and Type of Drugs. Int. J. Environ. Res. Public Health. 2021;18:5530. doi: 10.3390/ijerph18115530.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph18115530</ArticleId><ArticleId IdType="pmc">PMC8196755</ArticleId><ArticleId IdType="pubmed">34064096</ArticleId></ArticleIdList></Reference><Reference><Citation>Chilet-Rosell E., Ruiz-Cantero M.T., S&#xe1;ez J.F., Alvarez-Dardet C. Inequality in analgesic prescription in Spain. A gender development issue. Gac. Sanit. 2013;27:135&#x2013;142. doi: 10.1016/j.gaceta.2012.04.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gaceta.2012.04.014</ArticleId><ArticleId IdType="pubmed">22695368</ArticleId></ArticleIdList></Reference><Reference><Citation>Samuelsen P.J., Svendsen K., Wilsgaard T., Stubhaug A., Nielsen C.S., Eggen A.E. Persistent analgesic use and the association with chronic pain and other risk factors in the population-a longitudinal study from the Troms&#xf8; Study and the Norwegian Prescription Database. Eur. J. Clin. Pharmacol. 2016;72:977&#x2013;985. doi: 10.1007/s00228-016-2056-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00228-016-2056-7</ArticleId><ArticleId IdType="pubmed">27071993</ArticleId></ArticleIdList></Reference><Reference><Citation>da Silva Dal Pizzol T., Turmina Fontanella A., Cardoso Ferreira M.B., Bertoldi A.D., Boff Borges R., Serrate Mengue S. Analgesic use among the Brazilian population: Results from the National Survey on Access, Use and Promotion of Rational Use of Medicines (PNAUM) PLoS ONE. 2019;14:e0214329. doi: 10.1371/journal.pone.0214329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0214329</ArticleId><ArticleId IdType="pmc">PMC6428399</ArticleId><ArticleId IdType="pubmed">30897156</ArticleId></ArticleIdList></Reference><Reference><Citation>Grol-Prokopczyk H. Use and Opinions of Prescription Opioids Among Older American Adults: Sociodemographic Predictors. J. Gerontol. B Psychol. Sci. Soc. Sci. 2019;74:1009&#x2013;1019. doi: 10.1093/geronb/gby093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/geronb/gby093</ArticleId><ArticleId IdType="pmc">PMC6941497</ArticleId><ArticleId IdType="pubmed">30107532</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-Las-Pe&#xf1;as C., Cancela-Cilleruelo I., Moro-L&#xf3;pez-Menchero P., Rodr&#xed;guez-Jim&#xe9;nez J., G&#xf3;mez-Mayordomo V., Torres-Macho J., Pellicer-Valero O.J., Mart&#xed;n-Guerrero J.D., Hern&#xe1;ndez-Barrera V., Arendt-Nielsen L. Prevalence of Musculoskeletal Post-COVID Pain in Hospitalized COVID-19 Survivors Depending on Infection with the Historical, Alpha or Delta SARS-CoV-2. Var. Biomed. 2022;10:1951. doi: 10.3390/biomedicines10081951.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10081951</ArticleId><ArticleId IdType="pmc">PMC9406216</ArticleId><ArticleId IdType="pubmed">36009498</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594:259&#x2013;264. doi: 10.1038/s41586-021-03553-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03553-9</ArticleId><ArticleId IdType="pubmed">33887749</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherrer J.F., Miller-Matero L.R., Salas J., Sullivan M.D., Secrest S., Autio K., Wilson L., Amick M., De Bar L., Lustman P.J., et al. Characteristics of Patients with Non-Cancer Pain and Perceived Severity of COVID-19 Related Stress. Mo. Med. 2022;119:229&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9324720</ArticleId><ArticleId IdType="pubmed">36035570</ArticleId></ArticleIdList></Reference><Reference><Citation>Tubbs A.S., Ghani S.B., Naps M., Grandner M.A., Stein M.D., Chakravorty S. Past year use or misuse of an opioid is associated with use of a sedative-hypnotic medication: A NSDUH study. Clin. Sleep Med. 2021;18:809&#x2013;816. doi: 10.5664/jcsm.9724.</Citation><ArticleIdList><ArticleId IdType="doi">10.5664/jcsm.9724</ArticleId><ArticleId IdType="pmc">PMC8883103</ArticleId><ArticleId IdType="pubmed">34666879</ArticleId></ArticleIdList></Reference><Reference><Citation>Milani S.A., Raji M.A., Chen L., Kuo Y.F. Trends in the Use of Benzodiazepines, Z-Hypnotics, and Serotonergic drugs among US women and men before and during the COVID-19 pandemic. JAMA Netw. Open. 2021;4:e2131012. doi: 10.1001/jamanetworkopen.2021.31012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.31012</ArticleId><ArticleId IdType="pmc">PMC8546497</ArticleId><ArticleId IdType="pubmed">34694388</ArticleId></ArticleIdList></Reference><Reference><Citation>Czeisler M.&#xc9;., Lane R.I., Wiley J.F., Czeisler C.A., Howard M.E., Rajaratnam S.M.W. Follow-up survey of US adult reports of mental health, substance use, and suicidal ideation during the COVID-19 pandemic, September 2020. JAMA Netw. Open. 2021;4:e2037665. doi: 10.1001/jamanetworkopen.2020.37665.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.37665</ArticleId><ArticleId IdType="pmc">PMC7896196</ArticleId><ArticleId IdType="pubmed">33606030</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y., Xu E., Al-Aly Z. Risks of mental health outcomes in people with COVID-19: Cohort study. BMJ. 2022;376:e068993. doi: 10.1136/bmj-2021-068993.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-068993</ArticleId><ArticleId IdType="pmc">PMC8847881</ArticleId><ArticleId IdType="pubmed">35172971</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostinelli E.G., Smith K., Zangani C., Ostacher M.J., Lingford-Hughes A.R., Hong J.S.W., Macdonald O., Cipriani A. COVID-19 and substance use disorders: A review of international guidelines for frontline healthcare workers of addiction services. BMC Psychiatry. 2022;22:228. doi: 10.1186/s12888-022-03804-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12888-022-03804-7</ArticleId><ArticleId IdType="pmc">PMC8968241</ArticleId><ArticleId IdType="pubmed">35361184</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauschert C., Seitz N.N., Olderbak S., Pogarell O., Dreischulte T., Kraus L. Abuse of Non-opioid Analgesics in Germany: Prevalence and Associations Among Self-Medicated Users. Front. Psychiatry. 2022;13:864389. doi: 10.3389/fpsyt.2022.864389.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyt.2022.864389</ArticleId><ArticleId IdType="pmc">PMC9081647</ArticleId><ArticleId IdType="pubmed">35546935</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>